Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin’s Byetta LAR Lowers Glucose, Weight

This article was originally published in The Pink Sheet Daily

Executive Summary

Diabetes market is big enough for liraglutide and other drugs, Amylin CEO tells “The Pink Sheet” DAILY.

You may also be interested in...



Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps

Label with expanded language about thyroid cancer risk is expected.

Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps

Label with expanded language about thyroid cancer risk is expected.

Novo Nordisk’s Liraglutide Set For March 2009 PDUFA

Phase II study of once-weekly GLP-1 analog is under way, with results due next year.

Related Content

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel